Therapies aiming at alleviating these proteinopathies are currently being tested in other indications (BIIB100 for TDP-43 pathology in ALS; BIIB080 for Tau pathology in AD, see respective paragraphs above). This evidence concerns the gene TARDBP and Alzheimer disease.